文献速递血栓与止血

先天性血友病A中艾美赛珠单抗的药代动力学指导剂量减少:DosEmi研究的中期分析

Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study.
PubMed 文献 · J Thromb Haemost · 2025-11-07

DosEmi研究是一项正在进行中的多中心、开放标签、交叉荷兰试验,纳入26例重度血友病A参与者,比较常规艾美赛珠单抗给药6个月与药代动力学指导给药(目标谷浓度25-35 μg/mL)的出血控制。药代动力学指导给药使艾美赛珠单抗消耗量减少39%(范围13%-50%),无治疗出血参与者比例常规给药为69% vs 药代动力学指导给药为58%(风险差+11%;P=0.254),无关节出血比例分别为85% vs 88%(风险差-4%;P=0.500),年化出血率分别为0.7 vs 0.9(P=0.132)。中期结果提示药代动力学指导减少剂量后的出血控制与常规给药相似,所有预先设定的研究继续标准均满足。

要点

  • 药代动力学指导给药使艾美赛珠单抗消耗量减少39%(范围13%-50%)。
  • 无治疗出血参与者比例常规给药69% vs 药代动力学指导给药58%(风险差+11%;P=0.254)。
  • 年化出血率常规给药0.7 vs 药代动力学指导给药0.9(P=0.132)。

核心结论

  • 中期结果提示,药代动力学指导减少艾美赛珠单抗剂量(目标谷浓度25-35 μg/mL)的出血控制与常规给药相似。
  • 所有预先设定的研究继续标准和纳入年龄<16岁参与者的标准均已满足。

研究设计与样本

  • DosEmi研究(NCT06320626)是一项正在进行中的多中心、开放标签、交叉荷兰试验。
  • 符合条件的参与者年龄≥16岁,使用艾美赛珠单抗≥12个月且出血控制良好(≤2次治疗出血/6个月,无自发性出血)。
  • 本次计划的中期分析比较常规给药6个月与药代动力学指导给药的出血情况,共纳入26例重度血友病A参与者。
  • 研究继续标准为:无治疗出血参与者比例下降≤15%,总体自发性出血最多2次,年化出血率增加<1.0。

主要发现

  • 药代动力学指导给药使艾美赛珠单抗消耗量减少39%(范围13%-50%)。
  • 无治疗出血参与者比例常规给药为69% vs 药代动力学指导给药为58%(风险差+11%;P=0.254)。
  • 无关节出血参与者比例常规给药为85% vs 药代动力学指导给药为88%(风险差-4%;P=0.500)。
  • 年化出血率常规给药为0.7 vs 药代动力学指导给药为0.9(P=0.132),包括1次自发性肌肉出血(艾美赛珠单抗浓度52.5 μg/mL)。

关键数值与推荐

  • 药代动力学指导给药的目标谷浓度为25-35 μg/mL。
  • 研究继续标准:无治疗出血参与者比例下降≤15%,总体自发性出血最多2次,年化出血率增加<1.0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emicizumab provides effective prophylaxis for hemophilia A (HA), but its cost puts a burden on health care systems. Pharmacokinetic (PK)-pharmacodynamic analyses suggest that emicizumab is effective at lower trough concentrations (Ctrough) than the mean 55 μg/mL reported with conventional dosing. OBJECTIVES: To perform an interim analysis comparing bleeding control during 6 months of conventional emicizumab dosing vs PK-guided dosing in participants with HA, targeting a Ctrough of 25-35 μg/mL. METHODS: The DosEmi study (NCT06320626) is an ongoing multicenter, open-label, crossover Dutch trial. Eligible participants were aged ≥16 years using emicizumab for ≥12 months with good bleeding control (≤2 treated bleeds/6 months, none spontaneous). This planned interim analysis compared 6 months' bleeding on conventional dosing with PK-guided dosing. Study continuation criteria were ≤15% decrease in the proportion of participants without treated bleeds, maximum of 2 spontaneous bleeds overall, and <1.0 increase in bleeds/y (annualized bleeding rate). RESULTS: In 26 participants with severe HA, PK-guided dosing reduced emicizumab consumption by 39% (range, 13%-50%). The proportion of participants without treated bleeds was 69% with conventional dosing vs 58% with PK-guided dosing (risk difference, +11%; P = .254); the proportion without joint bleeds remained stable at 85% vs 88%, respectively (risk difference, -4%; P = .500). The annualized bleeding rate remained low (0.7 vs 0.9; P = .132), including 1 spontaneous muscle bleed (emicizumab concentration 52.5 μg/mL). CONCLUSION: These interim results suggest that bleeding control with PK-guided reduced emicizumab dosing (target Ctrough 25-35 μg/mL) is similar to conventional dosing. All prespecified criteria for study continuation and inclusion of participants aged <16 years were met.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. van der Zwet K, de Vos ADW, Cnossen MH, et al. Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study. J Thromb Haemost. 2025. PMID: 41207564. doi:10.1016/j.jtha.2025.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。